Youjia Bio Receives Recognition as Zhejiang Provincial Enterprise Research Institute, Ushering in a New Chapter of Innovation
YOUJIA BIO
Nucleic Acid Drug Developer
Recently, the public announcement period for the list of key enterprise research institutes and enterprise research institutes in Zhejiang Province proposed for recognition in 2025 by the Zhejiang Provincial Department of Economy and Information Technology has officially ended. Youjia (Hangzhou) Biomedical Technology Co., Ltd. (hereinafter referred to as "YOUJIA BIO") successfully passed the recognition with its strong technical capabilities in the field of nucleic acid drugs, continuous innovative achievements, and industry-leading potential, officially joining the ranks of "Zhejiang Provincial Enterprise Research Institutes." This honor not only represents high recognition from provincial authoritative departments of the company’s R&D strength but also marks that YOUJIA BIO is now qualified to independently undertake major provincial projects, laying a solid foundation for the company to deeply participate in the innovation layout of Zhejiang's biopharmaceutical industry and tackle key technical challenges in the industry.
Rigorous Screening at Every Level, Demonstrating Hardcore Innovation Strength
The accreditation of enterprise research institutes in Zhejiang Province undergoes multiple rounds of rigorous reviews, aiming to select a group of high-quality corporate innovation platforms that are technologically advanced, demonstrate outstanding innovation capabilities, and can drive industrial upgrading. The successful accreditation this time not only affirms YOUJIA BIO's years of dedication in the nucleic acid drug field but also demonstrates the company’s comprehensive strength in building innovative systems, achieving core technology breakthroughs, and cultivating talented teams.
Qualification Upgrade Empowers, Unlocking New Development Space
The recognition of this provincial-level enterprise research institute will create a "stacking effect" with existing qualifications, helping the company gain more support in industry-university-research cooperation, high-end talent cultivation, and innovation resource integration. Meanwhile,This is an important leap in development capabilities. The company will have more opportunities to participate in major technological breakthroughs across the province and take on core R&D tasks, further accelerating the process of key technology breakthroughs and the industrialization of achievements.
It is worth mentioning that the innovative strength of YOUJIA BIO has gained widespread recognition in the industry. The company has successively reached strategic cooperation with leading players in the industry, deeply collaborating in fields such as siRNA drug development and Antibody Oligonucleotide Conjugate (AOC) technology research and development. The establishment of this provincial-level corporate research institute will further promote more cross-disciplinary and high-level innovative collaborations.
Youjia (Hangzhou) Biomedical Technology Co., Ltd. (referred to as "YOUJIA BIO")YOUJIA BIO, founded in 2019 by returned postdoctoral fellows and seasoned industry experts, is a leader in the development of innovative nucleic acid technologies in China. The company is located in the Xiaoshan Economic and Technological Development Zone in Hangzhou, with 40 employees and nearly 1,500 square meters of R&D laboratories. Committed to the vision of ensuring that diseases have effective treatments, YOUJIA BIO strives to provide innovative therapeutic solutions tailored to clinical needs.
YOUJIA BIO has established the SEQUAD nucleic acid drug full-process development platform, which can rapidly advance the development of nucleic acid drugs and the industrialization of nucleic acid technology products.YOUJIA BIO is a 5213 Talent Project in Xiaoshan District, and has been approved as a Hangzhou-level R&D center, a Hangzhou New Eagle Enterprise, and a Zhejiang Province Specialized,精细化, and New Small and Medium-sized Enterprise.